1-3 of 3
Ho-Jae Han
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Asciminib Enhances Its Treatment Efficacy Synergistically in the Treatment of Chronic Myeloid Leukemia Harboring ABL1 Kinase Domain Mutation When Combined with a Reduced Dose of Ponatinib, Dasatinib, or Bosutinib, but Not with Nilotinib or Imatinib

Ho-Jae Han, Jaeyoon John Kim, Danielle Pyne, Anthea Travas, Amirthagowri Ambalavanan, Shinya Kimura, Michael W. Deininger, Jong-Won Kim, Dennis D. H. Kim
Journal: Blood
Blood (2023) 142 (Supplement 1): 6337.
https://doi.org/10.1182/blood-2023-188135
Published: 2023
Journal Articles

In Vitro Evidence of Synergistically Enhanced Efficacy of Axitinib When Combined with Asciminib in T315I Mutated Chronic Myeloid Leukemia

Ho-Jae Han, Eun-Ju Park, Jaeyoon John Kim, Danielle Pyne, Anthea Travas, Amirthagowri Ambalavanan, Shinya Kimura, Michael W. Deininger, Jong-Won Kim, Dennis D. H. Kim
Journal: Blood
Blood (2023) 142 (Supplement 1): 6336.
https://doi.org/10.1182/blood-2023-185440
Published: 2023
Journal Articles

In Vitro Evidence of Double Blockade of Asciminib with Reduced Dose of ATP-Binding Pocket Inhibitors in the Treatment of Chronic Myeloid Leukemia Harboring ABL1 Kinase Domain Mutation

Ho-Jae Han, Hyeok-Jae Jang, Youngseok Yoo, Taehyung Simon Kim, Jong-Won Kim, Dennis Dong Hwan Kim
Journal: Blood
Blood (2022) 140 (Supplement 1): 9588–9589.
https://doi.org/10.1182/blood-2022-165593
Published: 2022